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Atherosclerotic renal artery stenosis (ARAS) is associ-
ated with hypertension, ischemic nephropathy, and high 
cardiovascular risk. We review the data on revascular-
ization of the renal artery by percutaneous transluminal 
renal angioplasty (PTRA) and pharmacological therapy. 
In patients with severe ARAS and poorly controlled 
hypertension, PTRA can improve blood pressure con-
trol. In patients with rapid renal function loss and severe 
ARAS, PTRA can improve short-term renal function, 
but there is no evidence for long-term renoprotection. 
Recent evidence indicates that ARAS, and incidental 
renal artery stenosis, considerably increases cardiovas-
cular risk, independent of blood pressure, renal function, 
and prevalent risk factors. This suggests that revascular-
ization might potentially improve overall prognosis, but 
no data are available currently. The high cardiovascular 
risk warrants aggressive pharmacological treatment to 
prevent progression of the generalized vascular disor-
der. Ongoing trials will show whether revascularization 
has added, long-term effects on blood pressure, renal 
function, and cardiovascular prognosis.
Introduction
Atherosclerotic renal artery stenosis (ARAS) is associated 
with hypertension, ischemic nephropathy, cardiovascular 
disease [1,2], and a twofold to fivefold increase in cardio-
vascular mortality [3–5]. Furthermore, ARAS is assumed 
to account for 5% to 15% [6], or even 25% of new cases 
of end-stage renal failure [7]. The exact prevalence of 
ARAS in the general population is unknown because 
many cases remain undetected. In autopsies conducted 
after stroke [8] and myocardial infarction [9], the preva-
lence of ARAS was 10.4% and 12%, respectively. In a 
community-based screening for cardiovascular disease 
and risk factors from the United States, a prevalence of 
6.8% was reported in elderly subjects with a mean age 
of 77 years [10]. Clinical studies report widely different 
prevalences in populations with different clinical condi-
tions. In hypertensive subjects the prevalence of ARAS is 
less than 1% in unselected populations, whereas it is 5% 
in hospital-based populations, and up to 40% in third-
line referral clinics [11,12]. Among patients starting 
dialysis, the prevalence of ARAS was 31% in women and 
22% in men [13]. Finally, ARAS is frequently encoun-
tered as an incidental finding in patients who undergo 
routine angiography for peripheral vascular disease 
(PVD) or coronary artery disease; in these populations 
prevalence ranges from 5% to 40% [14–17,18•]. 
The treatment of ARAS has been a matter of dispute 
for a long time. In ARAS, as opposed to fibromuscular 
dysplasia, the narrowing of the renal artery is not an iso-
lated phenomenon, but is part of a process of generalized 
atherosclerosis. The Goldblatt phenomenon, which attri-
butes the driving force of the pathophysiologic events to 
increased activity of the renin-angiotensin system due to 
perfusion impairment in the post-stenotic kidney, may 
reflect relatively well the pathophysiologic mechanisms in 
experimental models and in renal artery stenosis (RAS) 
due to fibromuscular dysplasia, and is substantiated by 
the therapeutic benefits of revascularization by percuta-
neous transluminal renal angioplasty (PTRA) or surgery 
in this condition [19]. However, in ARAS the narrowing 
of the renal artery is not an isolated phenomenon, but 
part of a progressive process of generalized atherosclero-
sis. The impact of anatomical abnormalities in the renal 
artery as a driving force in the elevated, multi-organ 
cardiovascular risk in these patients, relative to other 
mechanisms of end-organ damage, is uncertain. It would 
seem logical to aim at revascularization of the kidney, 
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because this has the appeal of a causal intervention. 
Along this line of reasoning, several controlled trials 
demonstrated that PTRA can indeed lower blood pres-
sure and may prevent clinical events such as progressive 
renal failure [6]. The benefits and particularly the risks 
of intervention have not been well defined, however, and 
prospective randomized data that also consider long-
term outcome are lacking. 
On the other hand, there is increasing awareness that 
ARAS occurs in the context of generalized atherosclerosis. 
Based on current guidelines for hypertension [20,21], 
the high risk in patients with ARAS warrants aggressive 
treatment of the prevalent cardiovascular risk factors 
(eg, hypertension, hypercholesterolemia, glycemia) in all 
patients with ARAS. Possible benefits of revasculariza-
tion thus should outweigh those of optimal conservative 
intervention, and the possible benefit should be weighed 
against the risks of revascularization for individual 
patients. However, it should also be noted that in patients 
with ARAS, the risk for cardiovascular morbidity and 
mortality is greater than explained by blood pressure 
alone [1] and, remarkably, the presence of RAS in itself is 
an independent risk factor for cardiovascular morbidity 
and mortality [17,18•]. This raises the intriguing possibil-
ity that revascularization may contribute to improvement 
of overall outcome in high-risk subjects, even independent 
of blood pressure [18•,22].
 In this article we provide an overview of the available 
data on outcome of revascularization on top of (optimal) 
pharmacological therapy in ARAS on blood pressure, 
renal function, and prevention of cardiovascular events, 
and address the question whether the therapeutic effect 
of revascularization can be predicted, in order to be able 
to select the patients with ARAS who are likely to benefit 
from revascularization. 
PTRA: Effects on Blood Pressure 
Two types of revascularization procedures are available 
currently: PTRA with or without stenting, and surgical 
reconstruction. PTRA is currently the first choice because 
it is less invasive. Randomized data in patients with 
ostial ARAS showed that PTRA is as effective as surgical 
reconstruction, and moreover, a simpler procedure [23]. 
A recent meta-analysis of randomized controlled trials 
addressed the antihypertensive effect of balloon angio-
plasty versus standard medical therapy in ARAS [24]. 
The literature search identified three published clinical 
randomized trials: the EMMA trial [25]; the SNRASCG 
trial [26]; and the DRASTIC trial [27]. Altogether there 
were 210 patients in the three trials with moderate to 
severe (s 50%) unilateral or bilateral ARAS and poorly 
controlled hypertension who were followed for at least 
3 months (longest follow-up, 12 months) after interven-
tion. The pooled data using the 3-month follow-up values 
from the DRASTIC trial and the 6-month data from the 
two other trials showed a significantly greater decrease 
in both systolic and diastolic blood pressure from base-
line in the angioplasty group as compared with medical 
therapy. The weighted mean difference between the two 
treatments was -7 mm Hg (95% CI: -12 to -1 mm Hg) 
for systolic blood pressure and -3 mm Hg (95% CI: -6 
to -1 mm Hg) for diastolic blood pressure. Patients 
treated with balloon angioplasty (DRASTIC trial) were 
more likely to have patent renal arteries after 12 months 
(52% vs 19%; odds ratio = 4.2; 95% CI: 1.8 to 9.8), and 
had a significant decrease in median defined daily doses, 
in the EMMA trial at 6 months (P = 0.009), whereas in 
the DRASTIC trial at 3 months (P < 0.001). The number 
of antihypertensive drugs was also significantly lower in 
the balloon angioplasty group at both 3 and 12 months 
in the DRASTIC trial. This allows us to conclude that 
balloon angioplasty on top of standard medical therapy 
has a modest but significant effect on blood pressure 
compared to medical therapy alone. Unfortunately, to 
date there are no randomized studies comparing renal 
artery stenting to medication.
In a trial comparing PTRA plus stenting (PTRAS) to 
PTRA alone [28], PTRAS seemed to be a better technique 
than PTRA to achieve vessel patency in ostial ARAS. 
However, the two procedures did not differ in their effects 
on blood pressure outcome after 6 months of follow-up.
PTRA: Effects on Renal Function 
The natural course of the rate of renal function decline 
in patients with ARAS is uncertain. Progression of renal 
failure in patients with ARAS may reflect progression in 
the degree of narrowing of the renal artery, progression 
associated with ischemic nephropathy, or both. Rimmer 
and Gennari [6] reviewed five reports concerning serial 
angiograms in 237 patients with ARAS. Progression, 
including worsening of existing stenosis of the renal artery 
or the development of contralateral RAS, was reported 
in 116 patients (49%) during follow-up periods of 6 to 
18 months. Renal artery occlusion occurred in 28 cases 
(14%). In another report, the 3-year cumulative incidence 
of progression, defined as any detectable increase in the 
degree of diameter reduction affecting at least one renal 
artery, was 35% [29]. In a stepwise Cox proportional 
hazard analysis, baseline risk factors associated with pro-
gression were a systolic blood pressure of at least 160 mm 
Hg, diabetes mellitus, and high-grade (s 60% stenosis, or 
occlusion) ipsilateral or contralateral stenosis [29]. Thus 
far, the available randomized controlled trials focused 
on the effect of PTRA (on top of medical therapy) versus 
medical therapy alone on blood pressure [25–27]. The 
EMMA, SNRASCG, and DRASTIC studies are sum-
marized in Table 1. The studies separately did not show 
improvement of renal function. 
Because the lack of effect might be due to the limited 
power of the separate studies, due to their limited size 
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and relatively short follow-up, the previously mentioned 
meta-analysis [24] tried to combine the results of the three 
studies to see whether intervention could actually improve 
renal function outcome. However, because the effect on 
renal function was measured in different ways, the results 
could not be pooled.
The fact that there was no improvement of renal func-
tion, despite anatomically successful revascularization, may 
be explained in several ways. First, the patients included 
in these studies all had relatively normal renal function 
(EMMA and DRASTIC studies) or only mild renal insuf-
ficiency (SNRASCG study), so any improvement could 
be small as well and thus difficult to detect. Second, the 
specific pathophysiology of renal function impairment in 
ARAS should be taken into account. In unilateral ARAS 
glomerular filtration rate (GFR) does not reflect individual 
kidney function, because hyperfiltration in the normal 
kidney may compensate for reduced filtration in the 
ischemic kidney.
Moreover, renal failure may result from both isch-
emia of the stenotic kidney, resulting in progressive renal 
fibrosis and atrophy, and hypertensive nephropathy in the 
contralateral kidney. In the stenotic kidney, both in unilat-
eral and bilateral RAS, chronic ischemia may eventually 
result in irreversible damage to the renal parenchyma, so 
that dilating the stenotic lesion is no more than a “cosmetic” 
intervention. In this respect, La Batide-Alanore et al. 
[30•] evaluated split renal function (SRF, estimated by 
technetium 99mTc-diethylenetriamine penta-acetic acid scin-
tigraphy) outcome after PTRA in patients with unilateral 
Table 1. Effect of PTRA versus medication on renal function
Study 
Intervention, number of 
patients, n, mean follow-up, mo
Bilateral stenosis, 




Plouin et al. [25] Medication (standard), 
n = 26 (6 mo)
None eGFR* 73.2 mL/min + 0.6 mL/min (NS)




n = 14 (3–54 mo)
None Serum creatinine 1.87 mg/dL No change
PTRA, n = 13 1.53 mg/dL + 0.09 mg/dL (NS)
Medication, n = 16 28 (100%) 1.64 mg/dL + 0.04 mg/dL (NS)




n = 50 (12 mo)
24 (23%) eGFR* 60 mL/min 62 mL/min (NS)




PTRA, n = 18 (6 mo) None Total GFR 83 mL/min + 3 mL/min (NS)
GFR stenotic 
kidney




51 mL/min - 4 mL/min 
(P < 0.001)
Beutler et al. [31] PTRAS, stable creatinine, 
n = 26 (12 mo)
21 (33%) Serum creatinine 1.72 mg/dL + 0.04 mg/dL (NS)
PTRAS, deteriorating 
creatinine, n = 30
2.02 mg/dL - 0.31 mg/dL 
(P < 0.036)
Roussos et al. [33] PTRA, with deteriorating 
creatinine, n = 48 (12 mo)
11 (23%) eGFR† 23 mL/min + 7 mL/min 
(P = 0.072)
PTRA, with accelerating 
HT, n = 47
10 (21%) 37 mL/min + 1 mL/min (NS)
PTRA, with renal 
failure + HT, n = 25
7 (28%) 29 mL/min + 2 mL/min (NS)
PTRA, with PVD, n = 24 5 (21%) 29 mL/min + 1 mL/min (NS)
*eGFR estimated with use of Cockcroft-Gault formula (mL/min per 1.73 m2).
†eGFR estimated with abbreviated version of MDRD equation (mL/min per 1.73 m2).
eGFR—estimated glomerular ﬁltration rate; GFR—glomerular ﬁltration rate; HT—hypertension; NS—not signiﬁcant; PTRA—percutaneous 
transluminal renal angioplasty; PTRAS—PTRA plus stenting; PVD—peripheral vascular disease.
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RAS (s60%). They prospectively evaluated SRF and total 
GFR (clearance methods) after successful PTRA in 32 
consecutive hypertensive patients with RAS (18 atheroscle-
rotic and 14 with dysplastic disease) and a total GFR of at 
least 60 mL/min per 1.73 m2. Six months after successful 
PTRA, single-kidney GFR of the stenotic kidney had 
increased significantly, whereas concurrent single-kidney 
GFR of the nonstenotic kidney decreased significantly 
(Table 1). Thus, reversal of both the hypoperfusion of the 
stenotic side and the hyperperfusion of the nonstenotic 
side was observed, with a slight increase in total GFR as 
a net result. This elegant study nicely demonstrates that 
“early” successful revascularization of unilateral RAS 
(at least in patients with normal GFR) can facilitate res-
toration of the normal distribution of renal blood flow, 
and hence renal function, between the two kidneys. 
This presumably protects the stenotic kidney from isch-
emia, and the contralateral kidney from hyperfiltration 
that may contribute to long-term renal parenchymal 
damage, especially in the presence of systemic hyperten-
sion. However, it should be emphasized that randomized 
prospective trials are required to confirm the long-
term beneficial effects of the establishment of a new 
equilibrium after PTRA on prevention of further renal 
function deterioration.
Although randomized studies are still lacking, several 
nonrandomized studies showed improvement or even 
delay of dialysis after PTRA (with or without stenting) in 
patients with ARAS and severe renal dysfunction (Table 
1). Beutler et al. [31] demonstrated that in patients with 
pre-stent declining renal function (an increase in serum 
creatinine of s 20% in 12 months), PTRAS improved 
median serum creatinine in the first year (from 2.02 mg/dL 
[1.5 to 3.0 mg/dL] to 1.71 mg/dL [1.4 to 2.5 mg/dL]; 
P < 0.05) and remained stable during further follow-up 
monitoring (12 months after stent placement). The treat-
ment had no effect on serum creatinine levels if function 
had previously been stable. Similar results were reported 
by Korsakas et al. [32] in 28 patients with a serum cre-
atinine greater than 3.33 mg/dL, and progressive loss 
of renal function at least 1 year before angioplasty, in 
whom PTRA (with or without stent) significantly slowed 
progression of renal failure. A favorable outcome was 
correlated with a lower creatinine level (P = 0.0137) 
and a more rapid prior loss of renal function (r = 0.49, 
P = 0.020) at entry. Roussos et al. [33] showed that patients 
with ARAS who were referred for angioplasty because of 
deteriorating renal function (mean serum creatinine: 3.66 
± 1.89 mg/dL) had a small increase in glomerular filtration 
rate at 3-month follow-up (from 23 ± 11 to 27 ± 14 mL/
min/1.73 m2; P = 0.021). Analysis with patients who had 
both renal function deterioration and accelerated hyper-
tension showed improvement of glomerular filtration rate 
(from 25 ± 11 to 28 ± 14 mL/min/1.73 m2; P = 0.031) 3 
months after intervention. However, no statistically sig-
nificant difference was found 1 year after angioplasty. 
Several studies attempted to identify reliable predictors of 
renal function outcome after revascularization. Halimi et al. 
[34] reported that the effect of intervention (PTRA, n = 5; or 
surgery, n = 18) in a small heterogeneous group of ARAS 
patients was associated with pre-intervention albumin-
uria. On stepwise regression analysis, pre-intervention 
urinary albumin excretion was the only predictor of the 
response of renal function to intervention, with lack of 
improvement in albuminuric subjects. This suggests that, 
in ARAS, albuminuria is a marker of intrarenal parenchy-
mal damage that is not responsive to revascularization. 
This is in accord with data reported by Campo et al. [35] 
in 52 patients, who reported better outcome in renal func-
tion decline after PTRA in patients with proteinuria less 
than 1 g/day, serum creatinine less than 4 mg/dL, and 
low resistance index, respectively. In this study, neither 
kidney size nor rapid prior renal function deterioration 
predicted outcome after PTRA. A high resistance index, 
as assessed by Doppler ultrasonography, was also found 
to be a predictor of worse outcome after PTRA for blood 
pressure and renal function in the study by Radermacher 
et al. [36] in 138 ARAS patients. Unfortunately, however, 
many patients with ARAS are obese and thus not easily 
accessible for reliable Doppler sonography; moreover, 
the technique is relatively observer-dependent. The find-
ing of a small kidney size (< 8 cm) is considered a sign of 
renal failure, and PTRA on such small kidneys should not 
be undertaken, because it is unlikely that the risks out-
weigh the benefits—with the exception of ARAS patients 
entering dialysis programs. Despite small-sized (but not 
shrunken) kidneys, several patients could discontinue 
dialysis after PTRA [37]. Krijnen et al. [38] analyzed data 
from the DRASTIC study, and found that patients with 
bilateral stenosis benefit the most from immediate angio-
plasty with regard to renal function and blood pressure 
after 1 year of follow-up. 
In summary, data on the impact of PTRA on renal 
function are relatively sparse, and limited mainly to 
short-term studies. Whereas apparently PTRA can 
favorably affect overall renal function, such an effect 
is usually absent in subjects with stable renal function, 
or in those in whom irreversible parenchymal damage 
is present, as suggested by stable moderate to severe 
renal function impairment or albuminuria. Current 
data indicate that improvement of kidney function 
after renal vascularization (added to standard medical 
therapy) may be expected in patients with rapid dete-
rioration of renal function in the year or months before 
intervention, in whom renal function is nevertheless 
still relatively well preserved at the time of intervention. 
In selected cases, revascularization can result in renal 
function improvement even in patients in whom rapid 
renal function deterioration is so severe as to necessitate 
dialysis, as shown by case reports and Korsakas et al. 
[32]. In patients with normal to mildly impaired stable 
renal function, especially patients with unilateral RAS, 
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one cannot expect improvement of kidney function and 
the effect of revascularization for the long-term prog-
nosis is uncertain. 
PTRA: Effects on Prevention of Cardiovascular 
Events and Mortality
There are no randomized clinical trials evaluating the 
comparative effects of renal artery revascularization with 
medical therapy on cardiovascular morbidity and mortality 
in patients with ARAS, with or without co-morbid 
conditions [22]. Yet, in patients with ARAS the risk for 
premature cardiovascular death considerably exceeds 
their risk for progression to end-stage renal failure. The 
risk is particularly elevated in patients with lower baseline 
renal function, which was reported to predict mortality 
after PTRA [39]. 
This elevated risk was demonstrated recently by 
Kalra et al. [1] in a large randomly selected population 
cohort (n = 1,085,250) and an essentially similar picture 
emerges for patients with incidental RAS. Leertouwer et 
al. [15] showed that during 10 years of follow-up, if left 
untreated, incidental RAS did not lead to end-stage renal 
failure or the need for renal replacement therapy. Thus, 
revascularization is not recommended in incidentally dis-
covered RAS [14,15]. However, the risk of cardiovascular 
mortality is considerably increased, as demonstrated in a 
cohort of 491 patients with peripheral vascular disease, 
where incidental RAS was associated with an increased 
prevalence of not only kidney disease but also mortality 
(Fig. 1) [18•]. Cox regression analysis showed that RAS 
was an independent predictor of mortality (P = 0.005), 
along with age, diabetes, smoking, previous myocardial 
infarction, and stroke. Interestingly, inclusion of RAS in 
the multivariate analysis abolished the effects of hyper-
tension and renal function on mortality. Thus incidentally 
found RAS is a marker of poor prognosis. This is partly 
explained by its close association with extended cardio-
vascular disease, as well as with many established risk 
factors, such as older age [18•,40], impaired renal func-
tion [18], hypertension [18•,41], history of coronary artery 
disease [17,18•,40] and diabetes [18•,41]. However, in the 
above population with PVD, the increased risk for mor-
tality could not be explained fully by these factors, which 
accords with data from patients who undergo diagnostic 
cardiac catheterization simultaneously with an aortog-
raphy, in whom incidental RAS was an independent risk 
factor for mortality [17,42]. 
Moreover, the severity of RAS was related to mor-
tality. Whether the independent association between 
(incidental) ARAS and cardiovascular mortality impli-
cates a causal effect has not been established, but it 
is conceivable that neurohumoral activation from the 
ischemic kidney exerts unfavorable cardiovascular 
effects. If so, revascularization may have the potential 
to improve cardiovascular prognosis, even in incidental 
ARAS—as has been suggested for heart failure patients 
with ARAS [22]. Such studies, however, have not been 
performed. At any rate, from the point of view of their 
high risk profile, all patients with (incidental) ARAS 
should receive optimal pharmacological and supportive 
treatment to manage their cardiovascular risk, in 
compliance with current guidelines. It is known that 
rigorous treatment of hypertension and strict regula-
tion of diabetes improve cardiovascular morbidity 
and mortality [43–45] and that an intensive (supra-
optimal) regimen of lipid-lowering statin drugs can 
improve prognosis in high-risk populations, especially 
in patients with coronary artery disease and metabolic 
syndrome [46,47]. It would be of interest to test such 
strategies in patients with ARAS. 
Future Studies
Currently, four large randomized intervention trials are 
ongoing, with defined clinical endpoints as summarized in 
Table 2. The primary endpoint of the three ongoing trials 
from Europe is the kidney function. The STAR trial aims to 
compare the effects of renal artery stent placement together 
with optimal medication versus optimal medication alone 
on renal function in ARAS patients [48]. Patients are fol-
lowed for 2 years with extended follow-up to 5 years. The 
primary outcome of this study is a reduction in creatinine 
clearance greater than 20% compared to baseline. This 





































Figure 1. Kaplan-Meier survival plots for 491 patients with 
peripheral vascular disease, comparing outcomes for those with 
incidentally discovered renal artery stenosis (RAS) and those 
without renal artery stenosis (NRAS). On Cox regression analysis, 
the elevated risk for mortality in RAS was independent of blood 
pressure, renal function, and other cardiovascular risk factors.
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The NITER trial aims to evaluate whether medical 
therapy plus interventional PTRAS is superior to medical 
therapy alone according to the following combined pri-
mary endpoint: death or dialysis initiation or reduction 
by greater than 20% in estimated GFR after 0.5, 1, and 
2 years of follow-up and an extended follow-up until the 
fourth year [49]. The sample size is estimated in 50 patients 
per group to achieve a statistical significance of 0.05 in case 
of a reduction by 50% in the combined endpoints.
The ASTRAL study is the largest trial, with the inten-
tion to include 1000 patients, and compares angioplasty 
(with or without stenting, on top of medical therapy, free 
of choice) with medical therapy (free of choice) [50]. The 
progress of patients will be followed for at least a year. 
The primary comparison is the rate of progression of renal 
failure, as assessed by reciprocal creatinine plots over the 
course of the trial. Secondary endpoints include blood 
pressure control and the occurrence of serious vascular 
events (eg, myocardial infarction and stroke).
The latest trial is from the United States, the CORAL 
trial [51]. Randomization will occur in 1080 subjects. 
Optimal medical therapy alone compared to stenting with 
optimal medical therapy on a composite cardiovascular 
and renal endpoint (cardiovascular or renal death, myo-
cardial infarction, hospitalization for congestive heart 
failure, stroke, doubling of serum creatinine, and need 
for renal replacement therapy) will be studied. Hopefully, 
these studies have the potential to clarify the uncertainty 
concerning indications for, and outcomes after, renal 
revascularization in patients with ARAS.
Conclusions
ARAS is a condition associated with hypertension, renal 
function impairment, and a particularly high cardiovas-
cular risk. This requires optimal medical therapy aimed at 
treatment of the prevalent cardiac risk factors in all ARAS 
patients. Revascularization on top of medical therapy can 
improve blood pressure control in patients with severe 
ARAS and poorly controlled hypertension. Short-term 
improvement in renal function has been reported, but at 
this time there is no evidence that early revascularization 
can prevent long-term loss of renal function. However, in 
individuals with rapidly progressing renal function loss 
and severe ARAS, PTRAS can improve renal function. 
Recent evidence indicates that ARAS—and interestingly, 
incidental RAS—is associated with cardiovascular risk, 
also independent from blood pressure, renal function, 
and prevalent cardiovascular risk factors. This suggests 
that revascularization may have the potential to improve 
overall cardiovascular prognosis. Ongoing randomized 
trials in ARAS address the long-term effects of revascu-
larization, on top of pharmacological intervention, on 
blood pressure, renal function, and mortality. It is hoped 
that these trials will provide us with data that can guide 
clinical decision making in this grim condition. 
Clinical Trial Acronyms
ASTRAL—Angioplasty and Stent for Renal Artery 
Lesions; CORAL—Cardiovascular Outcomes in Renal 
Atherosclerotic Lesions; DRASTIC—Dutch Renal Artery 
Stenosis Intervention Cooperative; EMMA—Essai 
Multicentrique Medicaments vs Angioplastie; NITER—
Nephropathy Ischemic Therapy; SNRASCG—Scottish 
and Newcastle Renal Artery Stenosis Collaborative Group; 
STAR—Benefit of Stent Placement and Blood Pressure and 
Lipid-lowering for the Prevention of Progression of Renal 
Dysfunction Caused by Atherosclerotic Ostial Stenosis of 
the Renal Artery.
Table 2. Ongoing randomized trials with PTRAS versus medication
Randomized 
study
Intervention, number of intended 
patients, n, follow-up, y Primary endpoint Start study Data available
Bax et al. [48] PTRAS (on top of optimal medication*) 
vs optimal medication, n = 140, 2 y, 
extended to 5 y
Reduction in creatinine 
clearance > 20% 
compared to baseline
June 2000 Inclusion ended in 2006
Scarpioni et al. [49] PTRAS (on top of optimal medication*) 
vs optimal medication, n = 100, 2 y, 
extended to 4 y 
Death or dialysis 
initiation or reduction 
by > 20% in eGFR 
compared to baseline
January 2003 Last enrollment: 
January 2007
ASTRAL [50] PTRAS (standard medication) vs 
medication (standard), n = 750 (min), 
1 y, extended to 5 y
Mean slope of the 
reciprocal creatinine 
plot vs time
September 2000 Last enrollment: April 
2007 (641 patients 
included March 2006)
Cooper et al. [51] PTRAS (on top of optimal medication†)
versus optimal medication, 
n = 1080, 2 y
Event-free survival 
from CV and renal 
adverse events
2005 Last enrollment: 
December 2006 (last 
follow-up contact: 2009)
*Optimal medication: statins, antihypertensive drugs, and antiplatelet therapy.
†Optimal medication: ﬁrst-line drug angiotensin II type 1 receptor antagonist, other therapy according to JNC 7 report.
CV—cardiovascular; eGFR—estimated glomerular ﬁltration rate; JNC 7—Seventh Report of Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure; PTRA—percutaneous transluminal renal angioplasty; PTRAS—PTRA plus stenting.
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